Jul 02, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jul 01, 2021 4:30 pm EDT Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
Jun 07, 2021 10:30 am EDT Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect
Jun 04, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 14, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 13, 2021 4:01 pm EDT Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
May 10, 2021 8:30 am EDT Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer
May 07, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 04, 2021 4:01 pm EDT Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
Apr 27, 2021 5:51 pm EDT Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021